Date:	2023-8-23
Your Name:_ <u>></u>	gzhong Huang
Manuscript Tit	Exceptional Response to Immunotherapy Monotherapy in a Patient with Unfavorable Subset of
Cancer of Unk	n Primary
Manuscript nu	er (if known):
In the interest	ransparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	_None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	_None
3	Royalties or licenses	None	_None
4	Consulting fees	None	_None

5	Payment or honoraria for	None	_None
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	_None
	testimony		
7	Support for attending meetings and/or travel	None	_None
8	Patents planned, issued or	None	_None
	pending		
9	Participation on a Data	None	_None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	_None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	_None
12	Receipt of equipment,	None	_None
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	_None
	financial interests		

The author has no conflicts of interest to declare.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023-8-24	
Your Name:	:_ Dongqing Ren	
Manuscript	Title: Exceptional Response to Immunotherapy Monotherapy in a Patient with Unfavorable Subset of	
Cancer of U	nknown Primary	_
Manuscript	number (if known):	
•		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None

5	Payment or honoraria for lectures, presentations,	None	None
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
7	Command for additional to a	Al a sa a	Name
7	Support for attending meetings and/or travel	None	None
8	Patents planned, issued or	None	None
	pending		
•	5		
9	Participation on a Data Safety Monitoring Board or	None	None
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	None
11	Stock of Stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	None
	financial interests		

The author has no conflicts of interest to declare.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023-8-23	
Your Name:	Qiulian Sun	
Manuscript Title:	Exceptional	Response to Immunotherapy Monotherapy in a Patient with Unfavorable Subset of
Cancer of Unknow	wn Primary	
Manuscript numl	ber (if known):	
•	• • • • • • • • • • • • • • • • • • • •	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	None None
4	Consulting fees	None	None

5	Payment or honoraria for lectures, presentations,	None	None
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
7	Command for additional to a	Al a sa a	Name
7	Support for attending meetings and/or travel	None	None
8	Patents planned, issued or	None	None
	pending		
•	5		
9	Participation on a Data Safety Monitoring Board or	None	None
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	None
11	Stock of Stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	None
	financial interests		

The author has no conflicts of interest to declare.			

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2023-8-19		
	ur Name: Xinjian >		
Ma	anuscript Title: Exception	onal Response to Immunot	herapy Monotherapy in a Patient with Unfavorable Subset
Ca	ncer of Unknown Primary		
Ma	anuscript number (if known)):	
rel pa to rel Th ma Th to me	ated to the content of your rties whose interests may b transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare eation is not mentioned in apport for the work reported.	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	Inlanning of the work
1	All according to the according	1	None None
1	All support for the present manuscript (e.g., funding,	None	None
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	None
	any entity (if not indicated		
_	in item #1 above).		
3	Royalties or licenses	None	None
4	Consulting fees	None	None
		· 	

5	Payment or honoraria for lectures, presentations,	None	None
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
7	Command for additional to a	Al a sa a	Name
7	Support for attending meetings and/or travel	None	None
8	Patents planned, issued or	None	None
	pending		
•	5		
9	Participation on a Data Safety Monitoring Board or	None	None
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	None
11	Stock of Stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	None
	financial interests		

The author has no conflicts of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Date:	_2023-8-20
Your Nam <u>e:</u>	Yiwen Ding
Manuscript Title	: Exceptional Response to Immunotherapy Monotherapy in a Patient with Unfavorable Subset of
Cancer of Unkno	own Primary
Manuscript num	iber (if known):
•	. , , , , , , , , , , , , , , , , , , ,

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	None
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None

5	Payment or honoraria for lectures, presentations,	None	None
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
7	Command for additional to a	Al a sa a	Name
7	Support for attending meetings and/or travel	None	None
8	Patents planned, issued or	None	None
	pending		
•	5		
9	Participation on a Data Safety Monitoring Board or	None	None
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	None
11	Stock of Stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	None
	financial interests		

The author has no conflicts of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement: